Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination

Infection and Immunity

Volumn 67, Issue 12, 1999, Pages 6341-6345

  Tacket, Carol O ^a   Cohen, Mitchell B ^b   Wasserman, Steven S ^a   Losonsky, Genevieve ^a   Livio, Sofie ^a   Kotloff, Karen ^a   Edelman, Robert ^a   Kaper, James B ^a   Cryz, Stanley J ^c   Giannella, Ralph A ^b   Schiff, Gilbert ^b   Levine, Myron M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE;

ADULT; ANOREXIA; ARTICLE; CHOLERA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNITY; IMMUNOGENICITY; MALAISE; MALE; MULTICENTER STUDY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRAIN DIFFERENCE; VACCINATION; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CHOLERA; CHOLERA VACCINES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; VACCINATION; VIBRIO CHOLERAE;

EID: 0032721181     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Benenson, A. S., A. Saad, and W. H. Mosley. 1968. Serological studies in cholera. The vibriocidal response in cholera patients determined by a microtiter technique. Bull. W.H.O. 38:277-285.
2. Blake, P. A. 1993. Epidemiology of cholera in the Americas. Gastroenterol. Clin. North Am. 3:639-660.
3. Clemens, J. D., D. A. Sack, J. R. Harris, J. Chakraborty, M. R. Khan, S. Huda, F. Ahmed, J. Gomes, M. R. Rao, and A. M. Svennerholm. 1989. ABO blood groups and cholera: new observations on specificity of risk and modifications of vaccine efficacy. J. Infect. Dis. 159:770-773.
4. Clements, M. L., M. M. Levine, C. R. Young, R. E. Black, Y.-L. Lim, and R. M. Robins-Browne. 1982. Magnitude, kinetics and duration of vibriocidal antibody response in North Americans after ingestion of Vibrio cholerae. J. Infect. Dis. 145:465-473.
5. Cryz, S. J., Jr., M. M. Levine, J. B. Kaper, E. Fürer, and B. Althaus. 1990. Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 8:577-580.
6. Gangarosa, E. J., W. E. DeWitt, J. C. Feeley, and M. R. Adams. 1970. Significance of vibriocidal antibodies with regard to immunity to cholera. J. Infect. Dis. 121:S36-S43.
7. Gart, J. J., and J. Nam. 1988. Approximate interval estimation of the ratio of binomial parameters: a review and corrections for skewness. Biometrics 44:323-338.
8. Glass, R. I., M. Claeson, P. A. Blake, R. J. Waldman, and N. F. Pierce. 1991. Cholera in Africa: lessons on transmission and control for Latin America. Lancet 338:791-795.
9. Glass, R. I., J. Holmgren, C. E. Haley, M. R. Khan, A. M. Svennerholm, B. J. Stoll, K. M. Belayet Hossain, R. E. Black, M. Yunus, and D. Barua. 1985. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am. J. Epidemiol. 121:791-796.
10. Glass, R. I., A. M. Svennerholm, M. R. Khan, S. Huda, M. I. Huq, and J. Holmgren. 1985. Seroepidemiological studies of E1 Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236-242.
11. Gotuzzo, E., B. Butron, C. Seas, M. Penny, R. Ruiz, G. Losonsky, D. Lanata, S. Wasserman, E. Salazar, J. Kaper, S. Cryz, and M. Levine. 1993. The safety, immunogenicity and excretion pattern of single-dose live oral cholera vaccine, CVD 103-HgR in Peruvian adults of high and low socioeconomic level. Infect. Immun. 61:3994-3997.
12. Holmgren, J., A. M. Svennerholm, M. Jertborn, J. Clemens, D. A. Sack, R. Salenstedt, and H. Wigzell. 1992. An oral B subunit:whole cell vaccine against cholera. Vaccine 10:911-914.
13. Kenner, J. R., T. A. Coster, D. N. Taylor, A. F. Trofa, M. Barrera-Oro, T. Hyman, J. M. Adams, D. T. Beattie, K. P. Killeen, and D. R. Spriggs. 1995. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis. 172:1126-1129.
14. Ketley, J. M. J. Michalski, J. Galen, M. M. Levine, and J. B. Kaper. 1993. Construction of genetically marked Vibrio cholerae O1 vaccine strains. FEMS Microbiol. Lett. 111:15-22.
15. Kotloff, K. L., S. S. Wasserman, S. A. O'Donnell, G. A. Losonsky, S. J. Cryz, and M. M. Levine, 1992. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind cross-over trial. Infect. Immun. 60:4430-4432.
16. Lagos, R., A. Avendaño, I. Horwitz, V. Prado, C. Ferreccio, V. Sotomayor, G. Losonsky, S. Wasserman, S. Cryz, J. B. Kaper, and M. Levine. 1993. Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae O1 strain: a double-blind study in Chilean adults. Rev. Med. Chile 121:857-863.
17. Lagos, R., A. Avendaño, V. Prado, I. Horwitz, S. S. Wasserman, G. Losonsky, S. J. Cryz, Jr., J. B. Kaper, and M. M. Levine. 1995. Attenuated live oral cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect. Immun. 63:707-709.
18. Levine, M. M., and J. B. Kaper. 1993. Live oral vaccines against cholera: an update. Vaccine 11:207-212.
19. Levine, M. M., and J. B. Kaper. 1995. Live oral cholera vaccine: from principle to product. Bull. Inst. Pasteur 93:243-353.
20. Levine, M. M., J. B. Kaper, D. Herrington, J. Ketley, G. Losonsky, C. O. Tacket, B. Tall, and S. Cryz. 1988. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet ii:467-470.
21. Levine, M. M., and N. F. Pierce. 1992. Immunity and vaccine development, p. 285-327. In W. B. Greenough III and D. Barua (ed.), Cholera, Plenum Press, New York, N.Y.
22. Levine, M. M., and C. O. Tacket. 1995. Live oral vaccines against cholera, p. 233-258. In D. A. A. Ala'Aldeen and C. E. Hormaeche (ed.), Molecular and clinical aspects of bacterial vaccine development. John Wiley & Sons, Chichester, England.
23. Levine, M. M., C. R. Young, R. E. Black, Y. Takeda, and R. A. Finkelstein. 1985. Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains and to cholera toxin: application in serodiagnosis and seroepidemiology. J. Clin. Microbiol. 21:174-179.
24. Levine, M. M., C. R. Young, T. P. Hughes, S. O'Donnell, R. E. Black, M. L. Clements R. Robins-Browne, and Y.-L. Lim. 1981. Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology. Am. J. Epidemiol. 114:348-354.
25. Migasena, S., P. Pitisuttitham, B. Prayurahong, P. Suntharasami, W. Supanaranond, V. Desakorn, U. Vongsthongsri, B. Tall, J. Ketley, G. Losonsky, S. Cryz, J. B. Kaper, and M. M. Levine. 1989. Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults. Infect. Immun. 57:3261-3264.
26. Mintz, E. D., R. V. Tauxe, and M. M. Levine. 1998. The global resurgence of cholera, p. 63-104. In N. Noah and M. O'Mahony (ed.), Communicable disease: epidemiology and control. John Wiley & Sons, Chichester, England.
27. Perry, R. T., C. V. Plowe, B. Koumaré, K. L. Kotloff, G. A. Losonsky, S. S. Wasserman, and M. M. Levine. 1998. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and non-infected adults in Mali. Bull. W.H.O. 76:63-71.
28. Rennels, M. B., M. M. Levine, V. Daya, P. Angle, and C. Young. 1980. Selective vs. non-selective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories. J. Infect. Dis. 142:328-331.
29. Richie, E., N. H. Punjabi, Y. Sidharta, K. Peetosutan, M. Sukandar, S. S. Wasserman, M. Lesmana, Wangsasaputra, S. Pandam, M. M. Levine, P. O'Hanley, S. J. Cryz, and C. H. Simanjuntak. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Submitted for publication.
30. Sack, D. A., C. O. Tacket, M. B. Cohen, R. B. Sack, G. A. Losonsky, J. Shimko, J. P. Nataro, R. Edelman, M. M. Levine, R. A. Giannella, G. Schiff, and D. Lang. 1998. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect. Immun. 64:1968-1972.
31. Sanchez, J. L., and D. N. Taylor. 1997. Cholera. Lancet 349:1825-1830.
32. Simanjuntak, C. H., P. O'Hanley, N. H. Punjabi, F. Noriega, G. Pazzaglia, P. Dykstra, B. Kay, C. Suharyono, A. Budiarso, A. Rifai, S. S. Wasserman, G. A. Losonsky, J. Kaper, S. Cryz, and M. M. Levine. 1993. The safety, immunogenicity and transmissihility of single-dose live oral cholera vaccine CVD 103-HgR in 24 to 59 month old Indonesian children. J. Infect. Dis. 168:1169-1176.
33. Su-Arehawaratana, P. S., P. Singharaj, D. N. Taylor, C. Hoge, A. Trofa, K. Kuvanont, S. Migasena, P. Pitisuttitham, Y.-L. Lim, G. Losonsky, J. B. Kaper, S. S. Wasserman, S. Cryz, P. Echeverria, and M. M. Levine. 1992. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J. Infect. Dis. 165:1042-1048.
34. Suharyono, C., C. H. Simanjuntak, N. Witham, N. Punjabi, D. G. Heppner, G. A. Losonsky, H. Totosudirjo, A, R. Rifai, J. Clemens, Y. L. Lim, D. Burr, S. S. Wasserman, J. Kaper, K. Sorenson, S. Cryz, and M. M. Levine. 1992. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5 to 9-year-old Indonesian children. Lancet 340:689-694.
35. Tacket, C. O., G. Losonsky, J. P. Nataro, S. J. Cryz, R. Edelman, J. B. Kaper, and M. M. Levine. 1992. Onset and duration of protective immunity in challenged volunteers after vaccination with live oral cholera vaccine CVD 103-HgR. J. Infect. Dis. 166:837-841.
36. Taylor, D. N., J. Rizzo, R. Meza, J. Perez, and D. Watts. 1996. Cholera among Americans living in Peru. Clin. Infect. Dis. 22:1108-1109.
37. Weber, J. T., W. C. Levine, D. P. Hopkins, and R. V. Tauxe. 1994. Cholera in the United States, 1965-1991. Risks at home and abroad. Arch. Int. Med. 154:551-6.
38. Wiedermann, G., H. Kollaritsch, E. Jeschko, M. Kundi, C. Herzog, and B. Wegmuller. 1998. Adverse events after oral vaccination against cholera with CVD103-HgR. Wien. Klin. Wochenschr. 110:376-378.
39. Young, C. R., M. M. Levine, J. P. Craig, and R. Robins-Browne. 1980. Microtiter enzyme-linked immunosorbent assay for immunoglobulin G cholera antitoxin in humans: method and correlation with rabbit skin vascular permeability factor technique. Infect. Immun. 27:492-496.